The license agreement enables CCS to offer its customers transiently transfected
CAP-TTM cells for cell based assay and protein production applications.
The transient CAP-TTM protein production technology is based on CAP® cells, an immortalized cell line for stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
The collaboration combines CEVEC’s proprietary CAP-T expression system with CCS' expertise to produce and process bulk quantities of transiently transfected cells for drug discovery research in pharmaceutical companies worldwide.

CAP® cells is a registered trademark CEVEC Pharmaceuticals.